Anthracycline Cardiotoxicity: A New Paradigm for an Old Classic Running title: Groarke et al.; A new paradigm for anthracycline cardiotoxicity

Anthracycline cardiotoxicity: a new paradigm for an old classic.

A nthracyclines are potent antineoplastic agents with proven efficacy in the treatment of many pediatric and adult hematologic and solid organ cancers. Dose-dependent anthracycline-induced cardiomyopathy is the most notorious and well-studied chemotherapy-induced cardiovascular toxicity that was first described in 1971 in 67 patients treated with Adriamycin for a variety of tumors. 1 The clinic...

Early detection of anthracycline cardiotoxicity in a rabbit model: left ventricle filling pattern versus troponin T determination Running title: Early detection of anthracycline cardiotoxicity in rabbits

Evaluation of Anthracycline Effects on NT-ProBNP Plasma Level in Children with Malignancy

Background: NT-proBNP is a marker that is released from ventricles in response to pressure and volume overload. Raised plasma level of NT-proBNP is seen in ventricular dysfunction, ventricular muscular mass reduction or ventricular ischemia. Anthracyclines are widely used in treatment of pediatric cancer but their use is associated with cardiotoxicity which increases mortality and morbidity. We...

A journey in anthracycline-induced cardiotoxicity with emphasizing on doxorubicin: a review article

Cancer is the second leading cause of death in the United States and has become a health problem worldwide. The reported incidence of new cancer cases is estimated at 19.3 million, with a mortality rate of 10 million in the world in 2020. There are several therapeutic approaches for cancer, including chemotherapy. Chemotherapy is consuming anti-neoplastic drugs, alone or in combination. However...

Anthracycline cardiotoxicity after breast cancer treatment.

Anthracyclines are among the most active agents for the treatment of breast cancer; their use in combination regimens improves both disease-free and overall survival in patients with breast cancer. Unfortunately, the clinical utility of anthracycline use is limited by a cumulative dose-dependent cardiac toxicity resulting in congestive heart failure. As methods for detecting and treating breast...